Cite
HARVARD Citation
Hughes, A. et al. (2021). A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn's Disease. Journal of the Canadian Association of Gastroenterology. 4 (1), p. 48. [Online].